Drug Updates

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery KEYTRUDA Is Now Approved for the Adjuvant Treatment of Patients With RCC at Intermediate-High or High Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions KEYTRUDA Is the [...]

FDA Approves Amgen’s KYPROLIS (carfilzomib) Combination Regimen w/ DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) & dexamethasone For Patients w/ Multiple Myeloma At First Or Subsequent Relapse KYPROLIS in Combination With Subcutaneous Treatment Regimen Provides Further Options and Convenience for Patients With Relapsed/Refractory Multiple Myeloma THOUSAND OAKS, Calif., Dec. 1, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today [...]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection KEYTRUDA Is the First Anti-PD-1/L1 Therapy to Show Recurrence-Free Survival Benefit in the Adjuvant Setting for Stage IIB and IIC Melanoma KEYTRUDA Is Now [...]

U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD) Orencia is the first and only FDA-approved therapy to help prevent this serious complication that impacts between 30-70% of hematopoietic stem cell transplant recipients1     Approval [...]

Hidden in Plain Sight: We Already Have the Solution for High Drug Prices As leaders of a biosimilar company launched on the promise and value of biosimilars after the Affordable Care Act and a Louisiana community oncology practice working hard to utilize biosimilars, we believe biosimilars should be celebrated, rewarded, [...]

Gilead's Sacituzumab Govitecan-hziy (TRODELVY) is Now a Preferred Treatment Option, as Early as 2L For mTNBC SACITUZUMAB GOVITECAN-HZIY (TRODELVY) IS NOW A PREFERRED TREATMENT OPTION, AS EARLY AS 2L FOR mTNBC NCCN GUIDELINES®: Sacituzumab govitecan-hziy (TRODELVY) is recommended as a preferred treatment option* for adult patients with unresectable locally advanced [...]

Boehringer Ingelheim secures permanent J Code J1448 for COSELA™ (trilaciclib) Boehringer Ingelheim secures permanent J Code for COSELA™ (trilaciclib). The code, J1448, is effective on October 1, 2021. Visit COSELA.com for more information.

Understanding the Biden Administration’s Drug Pricing Plan The Department of Health and Human Services released the administration’s Comprehensive Plan for Addressing High Drug Prices in response to President Biden’s executive order that identified a lack of industry competition as a key driver of high drug prices.  READ MORE [...]

Amgen's 2021 Biosimilar Trends Report Released Competition created in part by biosimilars has led to significant savings for the healthcare system, potentially allowing these savings to be deployed to newer, innovative treatments. Take a deeper dive into the latest data in the eighth edition of Amgen's Biosimilar Trends Report, which [...]

New Indication Approved for Exelixis' Cabometyx Exelixis announces new indication for Cabometyx. Please see the attached package insert for the list of indications. The latest being: Adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted [...]